Macrophage adipocyte fatty acid-binding protein (FABP4) plays an important role in foam cell formation and development of atherosclerosis. Tamoxifen inhibits this disease process. In the present study, we determined whether the anti-atherogenic property of tamoxifen was related to its inhibition of macrophage FABP4 expression. We initially observed that tamoxifen inhibited macrophage/foam cell formation, but the inhibition was attenuated when FABP4 expression was selectively inhibited by siRNA. We then observed that tamoxifen and 4-hydroxytamoxifen inhibited FABP4 protein expression in primary macrophages isolated from both the male and female wild-type mice, suggesting that the inhibition is sex-independent. Tamoxifen and 4-hydroxytamoxifen inhibited macrophage FABP4 protein expression induced either by activation of GR (glucocorticoid receptor) or PPARγ (peroxisome-proliferator-activated receptor γ ). Associated with the decreased protein expression, Fabp4 mRNA expression and promoter activity were also inhibited by tamoxifen and 4-hydroxytamoxifen, indicating transcriptional regulation. Analysis of promoter activity and EMSA/ChIP assays indicated that tamoxifen and 4-hydroxytamoxifen activated the nGRE (negative glucocorticoid regulatory element), but inhibited the PPRE (PPARγ regulatory element) in the Fabp4 gene. In vivo, administration of tamoxifen to ApoE (apolipoprotein E)-deficient (apoE − / − ) mice on a high-fat diet decreased FABP4 expression in macrophages and adipose tissues as well as circulating FABP4 levels. Tamoxifen also inhibited FABP4 protein expression by human blood monocyte-derived macrophages. Taken together, the results of the present study show that tamoxifen inhibited FABP4 expression through the combined effects of GR and PPARγ signalling pathways. Our findings suggest that the inhibition of macrophage FABP4 expression can be attributed to the antiatherogenic properties of tamoxifen.
INTRODUCTION
FABPs (fatty acid-binding proteins) are a family of proteins with a small molecular mass and a high affinity for fatty acids [1] . FABPs facilitate the intracellular transport of hydrophobic fatty acids which are required to serve as an energy source and metabolic signals in cell growth/survival and inflammatory responses by activating enzymatic or transcriptional networks. On the basis of the expression pattern, FABPs can be classified as liver, intestinal, heart, adipocyte, epidermal, ileal, brain, myelin and testis FABP [2] . The adipocyte FABP (FABP4, A-FABP or aP2) is the bestcharacterized isoform among the entire FABP family. It was originally identified in adipose tissues and mature adipocytes [3] . In addition to fatty acid transport, FABP4 also plays an important role in other biological processes, particularly in many aspects of metabolic syndrome. Deficiency of FABP4 expression protects mice from hyperinsulinaemia and insulin resistance, and improves systemic glucose and lipid metabolism in the context of dietary or genetic obesity [4, 5] .
Expression of FABP4 can be regulated at both cellular and molecular levels [2] . During adipocyte differentiation, FABP4 is highly induced and regarded as a marker of terminal cell differentiation. Adipocyte differentiation in vitro is triggered by a combination of dexamethasone, insulin and isobutylmethylxanthine. The combination eventually induces expression of PPARγ (peroxisome-proliferator-activated receptor γ ), a ligand-activated transcription factor. PPARγ alone or in co-operation with C/EBPα (CCAAT/enhancer-binding protein α) induces expression of adipocyte-related molecules, including FABP4, and maintains the adipocyte phenotype [6] . At the molecular level, regulatory elements responding to activation of GR (glucocorticoid receptor) and PPARγ [pGRE (positive glucocorticoid regulatory element) and PPRE (PPARγ regulatory element)] exist [2] . Therefore both GR and PPARγ synthetic ligands, such as dexamethasone and TZDs (thiazolidinediones), can induce FABP4 expression in different cell types, including macrophages. In addition, our recent study shows a nGRE (negative GRE) in the Fabp4 promoter [7] . Statins, a class of HMG-CoA (3-hydroxy-3-methylglutarylCoA) reductase inhibitors which are used in treatment of hypercholesterolaemia patients, also possess non-cholesterollowering pleiotropic effects. Although statins alone reduce FABP4 expression [8] , they synergize dexamethasone-induced macrophage FABP4 expression by inactivating the nGRE [7] .
FABP4 is highly expressed in macrophages, suggesting the implication of FABP4 in macrophage/foam cell formation and the development of atherosclerosis. In vitro, overexpressing FABP4 facilitates foam cell formation in human THP-1
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macrophages [9] . In vivo, genetic deletion of FABP4 expression inhibits high-fat-diet-induced atherosclerosis in mice without significant changes in serum lipids or insulin sensitivity [10] [11] [12] . More importantly, lack of FABP4 expression specifically in macrophages by bone marrow transplantation inhibits lesion development, suggesting an important role for macrophage FABP4 in atherosclerosis [11] . Deficiency of FABP4 expression in macrophages results in decreased cholesteryl ester accumulation and secretion of inflammatory cytokines [TNFα (tumour necrosis factor α), MCP-1 (monocyte chemoattractant protein-1) and IL (interleukin) -6] , and resistance to PMA-induced inflammatory cytokines (TNFα, IL-1β and IL-6) [11] . Clinically, it has been reported that the FABP4 levels in atherosclerotic lesions are associated with an unstable plaque phenotype and an increased risk for cardiovascular events [13] . A 10-year prospective study demonstrates that circulating FABP4 levels are associated with long-term prognosis in patients with coronary heart disease and may represent an important pathophysiological mediator of atherosclerosis [14] . Tamoxifen and its derivative, 4-hydroxytamoxifen, are selective ER (oestrogen receptor) modulators [15] . Dependent on the target cell types/tissues, tamoxifen functions either as an agonist or antagonist [16] . For instance, in breast tissue, tamoxifen inactivates the ER, thereby inhibiting the growth of breast cancer cells. In endometrium, tamoxifen behaves as an agonist. Clinically, tamoxifen has been used for more than two decades to treat both early and advanced ER-positive breast cancer in women, and as the most common hormone treatment for male breast cancer. Tamoxifen also has a preventive effect on breast cancer in women with a high risk of developing the disease [17] .
Tamoxifen has been demonstrated to have multiple pleiotropic biological effects. Both pre-clinical and clinical studies have suggested the cardioprotective properties of tamoxifen. For example, tamoxifen reduces the incidence of fatal myocardial infarction and the intima-media thickness of the common carotid artery in post-menopausal women. It also increases ED-FMD (endothelium-dependent flow-mediated dilation) in men with advanced atherosclerosis [18] [19] [20] . In animal models, tamoxifen reduces atherosclerotic lesions induced by high-fat diet in both wild-type and ApoE (apolipoprotein E)-deficient (apoE − / − ) mice and surgically post-menopausal monkeys [21] [22] [23] .
It is also well known that atherosclerosis is an underlying cause of coronary heart disease. The lipid-laden macrophage/foam cells are a prominent part of atherosclerotic lesions. Thus the formation of foam cells is an initial and critical step in lesion development [24] . Although tamoxifen has been shown to have anti-atherogenic properties, the molecular mechanisms involved which define its role are unknown. Therefore we hypothesize that macrophage FABP4 is a molecular target of tamoxifen. The inhibition of macrophage FABP4 expression can be, at least in part, attributed to the tamoxifen effects on macrophage/foam cell formation and atherosclerosis. In the present study, we attempt to identify the signalling pathways by which tamoxifen can regulate macrophage FABP4 expression.
MATERIALS AND METHODS

Materials
Fulvestrant (ICI182780) was purchased from Cayman Chemical. Tamoxifen, 4-hydroxytamoxifen, 17β-oestradiol and other chemicals were purchased from Sigma-Aldrich. Goat anti-(mouse FABP4), rabbit anti-(mouse GR) and rabbit anti-(mouse PPARγ ) polyclonal antibodies were obtained from Santa Cruz Biotechnology.
Cell culture and in vivo study HEK (human embryonic kidney)-293T cells were purchased from the A.T.C.C. and cultured in complete DMEM (Dulbecco's modified Eagle's medium) containing 10 % FBS, 50 μg/ml penicillin/ streptomycin and 2 mM glutamine. Cells at 95 % confluence were used for transfection and analysis of promoter activity.
The protocol for animal studies was approved by the Ethics Committee of Nankai University and conforms to the Guide for the Care and Use of Laboratory Animals published by the NIH (National Institutes of Health). C57BL/6 wild-type mice and ApoE-deficient mice (apoE − / − ) purchased from the Jackson Laboratory were bred at the Animal Center of Nankai University. Mouse peritoneal macrophages were collected as follows. Mice at approximately 8 weeks old were injected intraperitoneally with 3 ml of 4 % thioglycollate solution and maintained with access to water and normal chow for 5 days. The animals were anaesthetized and killed within a CO 2 chamber. The peritoneal macrophages were collected from the mouse abdomen by lavage with PBS. Cells were cultured in complete RPMI 1640 medium containing 10 % FBS, 50 μg/ml penicillin/streptomycin and 2 mM glutamine for 2 h. After the removal of all floating cells, the adhesive cells (macrophages) were cultured in complete RPMI 1640 medium for a further 2 days followed by treatment in serumfree medium.
To investigate the effect of tamoxifen on macrophage and adipose tissue FABP4 expression as well as the circulating FABP4 levels in vivo, both male and female apoE − / − mice (∼ 8-week-old) were fed a high-fat diet (0.5 % cholesterol and 21 % fat) or the diet containing tamoxifen (2 mg/100 g of food) for 1 month. The mice were injected intraperitoneally with 4 % thioglycollate solution 5 days before the end of the experiments. After killing, mouse blood, peritoneal macrophages, and both white and brown adipose tissues were individually collected. Blood samples were kept for more than 2 h at room temperature (22 • C). After centrifugation for 20 min at 2000 g (at room temperature), the serum was transferred into a new test tube and kept at − 20
• C until assaying of circulating FABP4 using an ELISA assay kit purchased from USCN Life Science. Total cellular proteins were extracted from the above macrophage or tissue samples for determination of FABP4 protein expression.
Human blood monocyte-derived macrophages were obtained as described previously with blood obtained from a healthy donor (Tianjin Blood Bank, China) [25] . Briefly, after removal of red blood cells by incubating the blood with dextran sedimentation mixture, the remained cells were collected by centrifugation (250 g for 5 min at 4
• C) and re-suspended in serum-free RPMI 1640 medium. The suspension was overlaid on the top of a FicollHypaque solution. After gradient centrifugation for 20 min at 1000 g, monocytes in the interface layer were collected and washed twice with serum-free medium followed by culture in complete RPMI 1640 medium (20 % FBS) for 7 days to differentiate into macrophages.
Inhibition of macrophage FABP4 expression by siRNA and determination of foam cell formation
The siRNA against FABP4 (FABP4 siRNA) with the target sequence of 5 -AATGTAGTGTTTGATGCAAAT-3 was constructed using the Ambion Silencer siRNA Construction kit (Invitrogen). Peritoneal macrophages isolated from male apoE − / − mice were plated in six-well plates (for the transfection efficiency assay) or on coated 12-mm glass slides in 24-well plates (for Oil Red O staining) and transfected with scrambled siRNA or FABP4 siRNA using Lipofectamine TM (Invitrogen) in RPMI 1640 medium. After 6 h of transfection, the same volume of medium was added to the cells and the transfection was continued for another 24 h. The transfected cells were then switched into complete medium for another 48 h followed by extraction of total cellular protein or determination of foam cell formation as follows. The transfected cells were treated with 5 μM tamoxifen or 4-hydroxytamoxifen for 12 h followed by incubation with 50 μg/ml oxLDL [oxidized LDL (low-density lipoprotein)] for 2 h. The cells were then fixed in 4 % paraformaldehyde for 30 min, washed twice with PBS for 5 min, and stained with Oil Red O solution (a mixture of three parts 0.5 % Oil Red O in propan-2-ol and two parts water) for 50 min at room temperature followed by washing twice with water. The cells were then re-stained with a haematoxylin solution for 30 s, kept in water for 5 min and photographed. Cells containing lipid droplets (more than ten) were counted as foam cells and at least ten fields of each sample were counted for quantitative analysis [26] .
Determination of FABP4 protein expression by Western blot analysis
After treatment, cells were washed twice with ice-cold PBS and lysed with a lysis buffer [20 mM Tris (pH 7.5), 137 mM NaCl, 2 mM EDTA, 1 % Triton X-100, 25 mM 2-glycerophosphate, 2 mM sodium pyrophosphate, 1 mM PMSF, 10 μg/ml aprotinin/ leupeptin and 100 mM sodium orthovanadate]. The cellular lysate was spun for 10 min at 16 200 g at 4
• C, and the supernatant was transferred into a new test tube. Proteins (40 μg) from each sample were separated by SDS/PAGE (15 % gel) and transferred on to a nylon-enhanced nitrocellulose membrane. The membrane was blocked with a solution of 5 % BSA in PBS for 1 h, and then incubated with a goat anti-(mouse FABP4) polyclonal antibody for 1 h at room temperature followed by washing for 3×10 min with a solution of PBS-T (0.5 % Tween 20/PBS). The membrane was then exposed to HRP (horseradish peroxidase)-conjugated rabbit anti-(goat IgG) and incubated for 1 h at room temperature. After three washes with PBS-T (10 min each), the membrane was incubated for 5 min in a mixture of equal volumes of Western blot chemiluminescence reagents 1 and 2 (Millipore). The membrane was then exposed to film for development.
Isolation of total RNA, purification of poly(A + ) RNA and Northern blot analysis of macrophage Fabp4 mRNA expression
After treatment, cells were used to extract total cellular RNA. The poly(A + ) RNA isolated from 100 μg of total RNA was used to conduct Northern blot analysis of Fabp4 mRNA expression as described previously [27] .
Preparation of plasmid DNA and determination of FABP4 promoter activity
The GRα expression vector was prepared as described previously [7] . The PPARγ 2 expression vector was prepared as follows. A cDNA encoding mouse Ppargamma2 was generated by reverse transcription with total RNA isolated from the differentiated 3T3-L1 cells and oligo(dT) 18 primer. A PCR was carried out with the cDNA and the primers 5 -TCTCGAGCTCAATGGGTGAA-ACTCTGGGAG-3 (forward) and 5 -CCGCGGTACCCTAAT-ACAAGTCCTTGTAGATCTCCT-3 (reverse). After the sequence was confirmed, the PCR product was digested with SacI and KpnI and then subcloned into an expression vector, pEGFP-C2 (pC2-PPARγ ).
A mouse Fabp4 promoter (from − 4029 to + 25) was constructed by PCR with mouse genomic DNA and the following primers: 5 -CCGCTCGAGAGACACAAACAGAGCAAATG-3 (forward) and 5 -CCCAAGCTTAGGAGCTGTCTTCCAGGTG-3 (reverse). After the sequence was confirmed, the PCR product was digested with XhoI and HindIII followed by ligation with the pGL4 luciferase reporter vector from Promega (pFABP4-4K), transformed into Escherichia coli for amplification. The Fabp4 promoter with PPRE1 (from − 3693 to − 3681) deletion (pFABP4-4K-PPRE1del) or PPRE2 (from − 2033 to − 2021) deletion (pFABP4-4K-PPRE2del) was constructed using the Phusion Site-Directed Mutagenesis kit from New England Biolabs with pFABP4-4K DNA and primers with the corresponding PPRE deletion respectively. To disclose the role of the nGRE or pGRE (nGRE is from − 114 to − 99; pGRE is from − 416 to − 411) [7] in tamoxifen-mediated Fabp4 promoter activity, another Fabp4 promoter (from − 1880 to + 25, pFABP4-1.9K) containing no PPRE was constructed by PCR with pFABP4-4K and primer 5 -CCGCTCGAGGAAATTTTCACGATGCATTGC-3 (forward) and the same reverse primer as above. The promoter with nGRE deletion was constructed with pFABP4-1.9K and the primers with nGRE deletion. To analyse FABP4 promoter activity, HEK-293T cells at ∼ 95 % confluence in 24-well plates were transfected with the DNA of the FABP4 promoter or pC2-GR or pC2-PPARγ and Renilla (for internal normalization) using Lipofectamine TM 2000 (Invitrogen). After 24 h transfection plus treatment, the cells were lysed and the cellular lysate was used to determine the activity of firefly and Renilla luciferases using the Dual-Luciferase Reporter Assay system (Promega).
EMSA and ChIP assay of GR or PPARγ DNA-binding activity
After treatment, nuclear protein was extracted from the cells and was used for an EMSA to analyse the binding of nGRE and PPRE1 as described previously [28] . The sequences of the nGRE and PPRE1 probes were GGTCATGAAGgaaaTGATCTGGCC and AAAGTAGGTCAcAGTTTATCTGCAG respectively (the underlined nucleotides are putative nGRE and PPRE in FABP4 in which the uppercase letters are conserved nucleotides, whereas the lowercase letters are variable nucleotides).
The ChIP assay was conducted as follows. After treatment, cells were cross-linked by the addition of formaldehyde and then sonicated in a lysis buffer [50 mM Hepes-KOH (pH 7.5), 140 mM NaCl, 1 % Triton X-100, 1 mM EDTA, 0.1 % sodium deoxycholate, 0.1 % SDS and protease inhibitors aprotinin/leupeptin] to fragment DNA into an average size of 500-1000 bp. The input PCR was conducted with DNA extracted from the sonicated chromatin after reversal of the cross-linking. Immunoprecipitation was conducted with the same amount of chromatin from each sample based on the input and anti-PPARγ or anti-GR polyclonal antibody, followed by PCR. The primers for the ChIP assays were: PPRE1, 5 -GG-CCTGCTGGTAAGTTCTTC-3 (forward) and 5 -GTAAAGAC-AGACTGAGAGTG-3 (reverse); nGRE, 5 -GTACTCTAAGTC-CAGTGATC-3 (forward) and 5 -GTAAACCTTCGAGGAGG-AGC-3 (reverse).
Data analysis
Data were generated from three independent experiments. All statistical results were obtained by Student's t test using GraphPad Prism. P < 0.05 was considered significant.
RESULTS
Tamoxifen inhibits macrophage FABP4 expression in a sex-independent manner
To determine whether tamoxifen inhibits macrophage/foam cell formation by its effect on macrophage FABP4 expression, we isolated peritoneal macrophages from male apoE − / − mice. We transfected the cells with FABP4 siRNA at different concentrations for 3 days and then determined FABP4 protein expression. Compared with scrambled siRNA, FABP4 siRNA reduced macrophage FABP4 protein expression in a concentration-dependent manner ( Figure 1A) . We then determined the effects of tamoxifen and 4-hydroxytamoxifen on macrophage/foam cell formation and investigated whether the inhibitory effect is related to FABP4 expression. After 3 days of transfection with scrambled or FABP4 siRNA, the cells were treated with tamoxifen or 4-hydroxytamoxifen and foam cell formation was assessed. The results shown in Figure 1(B) indicate that tamoxifen or 4-hydroxytamoxifen reduced lipid accumulation in the cells transfected with scrambled siRNA, indicating inhibition of foam cell formation (top panel of Figure 1B ). The reduction in macrophage FABP4 expression by siRNA also decreased lipid accumulation by macrophages. Interestingly, compared with scrambled siRNA, inhibition of FABP4 expression by siRNA attenuated the inhibitory effect of tamoxifen on lipid accumulation in macrophages ( Figure 1B) , indicating that the inhibition of foam cell formation by tamoxifen was related to its effect on FABP4 expression.
To test the effect of tamoxifen on macrophage FABP4 expression and whether the effect is sex-related, we isolated peritoneal macrophages from both male and female C57BL/6 wild-type mice and treated the cells with tamoxifen and 4-hydroxytamoxifen at different concentrations overnight. The results of Western blot analysis indicate that tamoxifen or 4-hydroxtamoxifen inhibited FABP4 protein expression in macrophages isolated either from male or female mice. The inhibition was concentration-dependent, with a greater effect on cells isolated from male mice (Figures 2A and 2B) . We also conducted a time-course study in which the cells were treated with 5 μM tamoxifen or 4-hydroxtamoxifen for different times. The results in Figures 2(C) and 2(D) show that the inhibition occurred quickly (∼ 2 h) and reached a steady state after 6 h of treatment. Similarly, we treated the macrophages with either an ER agonist (17β-oestradiol) or antagonist (fulvestrant or ICI182780). 17β-Oestradiol reduced macrophage FABP4 protein expression in a sex-independent manner (Figures 2E and 2F) . Fulvestrant slightly inhibited FABP4 protein expression in macrophages isolated from female mice (Figure 2G ), but slightly increased expression in the cells isolated from male mice at high concentrations ( Figure 2H ). Taken together, the results in Figure 2 indicate that tamoxifen inhibited macrophage FABP4 expression in a sex-independent manner. Owing to the similar inhibitory effects of tamoxifen on FABP4 expression between peritoneal macrophages isolated from male and female mice, we chose to conduct the rest of our in vitro experiments with cells isolated from male C57BL/6 wild-type mice.
Tamoxifen inhibits GR or PPARγ -induced macrophage FABP4 expression
Macrophage FABP4 expression can be activated by ligands for the GR, such as dexamethasone, and the activation can be synergized by statins [7] . To test whether tamoxifen is able to antagonize the above induction of FABP4 expression, we treated macrophages with tamoxifen or 4-hydroxytamoxifen at different concentrations in the presence or absence of dexamethasone. Expression of FABP4 protein was induced ∼ 2.5-fold by dexamethasone. However, both tamoxifen and 4-hydroxytamoxifen blocked this induction in a concentrationdependent manner ( Figure 3A) . The co-treatment of macrophages with dexamethasone and pitavastatin further induced macrophage FABP4 protein expression (>3-fold). However, tamoxifen or 4-hydroxytamoxifen displayed a similar inhibitory effect on this induction as with dexamethasone alone (Figures 3B and 3C) . Therefore the inhibition of FABP4 expression by tamoxifen may be related to its inactivation of the GR, although we observed that tamoxifen or 4-hydroxytamoxifen had little effect on GR expression and dexamethasone-induced GR nuclear translocation (results not shown).
To determine whether the inhibition of FABP4 protein expression by tamoxifen was associated with FABP4 mRNA expression, we conducted Northern blot analysis to determine the expression of macrophage Fabp4 mRNA in response to tamoxifen and 4-hydroxytamoxifen. Expression of Fabp4 mRNA in control macrophages is undetectable, but can be significantly induced by dexamethasone or dexamethasone plus pitavastatin [7, 27] . Therefore we determined the effect of tamoxifen on macrophage Fabp4 mRNA expression in the presence of dexamethasone or dexamethasone plus pitavastatin. The results of both concentration and time-course studies ( Figures 4A and 4B) demonstrate that tamoxifen or 4-hydroxytamoxifen can inhibit the induction of Fabp4 mRNA expression. These findings indicate that tamoxifen may regulate FABP4 transcription.
PPARγ , a transcription factor, can be activated by natural ligands such as 15-deoxy 12,14 prostaglandin J2, oxLDL and synthetic ligands, such as TZDs. Activation of PPARγ can also induce macrophage FABP4 expression [29] [30] [31] . To test whether the inhibition of macrophage FABP4 expression by tamoxifen is related to inactivation of PPARγ , we initially treated cells with tamoxifen or 4-hydroxytamoxifen in the presence of and 5B). Troglitazone is a synthetic PPARγ ligand. Treatment of macrophages with troglitazone increased FABP4 protein expression (∼ 3-fold). However, the induction was reduced by tamoxifen and 4-hydroxytamoxifen ( Figure 5C ). In particular, 4-hydroxytamoxifen totally blocked the increased FABP4 protein expression. To further identify the mechanism by which tamoxifen inhibits PPARγ -induced FABP4 expression, we determined the effect of tamoxifen or 4-hydroxytamoxifen on PPARγ expression. As seen in Figure 5 (D), PPARγ protein expression was reduced by tamoxifen and 4-hydroxytamoxifen.
Inhibition of macrophage FABP4 expression by tamoxifen occurs at the transcriptional level
To further characterize the inhibition of FABP4 expression by tamoxifen, we constructed a Fabp4 promoter (pFABP4-1.9K, from − 1880 to + 25, Figure 6A ) which includes both the pGRE (from − 416 to − 411) and nGRE (from − 114 to − 99). The results in Figure 6 (B) indicate that both tamoxifen and 4-hydroxytamoxifen inhibited pFABP4-1.9K promoter activity.
Highly expressing GR alone by transfection of cells with a GR expression vector had little effect on pFABP4-1.9K activity, but significantly increased the promoter activity when the highly expressed GR was activated by dexamethasone. However, both tamoxifen and 4-hydroxytamoxifen blocked the induction by GR activation ( Figure 6C ). Interestingly, when the nGRE (ATGAAGgaaaTGATCT, from − 114 to − 99) was deleted from the pFABP4-1.9K promoter [7] , both tamoxifen and 4-hydroxytamoxifen had little effect on the promoter activity ( Figure 6D ), suggesting that tamoxifen and 4-hydroxytamoxifen enhanced the nGRE activity.
To test the effect of tamoxifen on PPARγ -induced FABP4 transcription, we constructed another Fabp4 promoter (pFABP4-4K, from − 4029 to + 25, Figure 6A ), which includes two putative PPREs (PPRE1, AGGTCAcAGTTTA, from − 3693 to − 3681; PPRE2, AGAGCAcAGAGCA, from − 2033 to − 2021; the underlined nucleotides are identical with the sequence of the conserved PPRE, AGGTCAnAGGTCA). pFABP4-4K also contains nGRE thus, compared with the effect on pFABP4-1.9K, tamoxifen and 4-hydroxytamoxifen demonstrated greater inhibition on pFABP4-4K ( Figure 6E ). Overexpressing PPARγ alone induced pFABP4-4K activity, and activation of PPARγ by troglitazone further increased the promoter activity. However, the activation was blocked by tamoxifen and 4-hydroxytamoxifen in a concentration-dependent manner ( Figure 6F ), indicating the inactivation of PPARγ by tamoxifen. To distinguish the role of PPRE1 and PPRE2 in regulation of FABP4 transcription, we constructed the promoter with deletion of PPRE1 or PPRE2, and determined activity of the promoter in response to treatment. As
Figure 4 Tamoxifen and 4-hydroxytamoxifen inhibit macrophage Fabp4 mRNA expression
After treatment, peritoneal macrophages isolated from male C57BL/6 mice were used to extract total cellular RNA. Poly(A + ) RNA was isolated from 100 μg of total RNA and used to determine macrophage Fabp4 mRNA expression by Northern blot analysis as described in the Materials and methods section. The same blot was re-hybridized with a 32 P-labelled GAPDH (glyceraldehyde-3-phosphate dehydrogenase) probe as an internal control. shown in Figure 6 (G), the deletion of PPRE1, but not PPRE2, dramatically decreased the inductive effect of PPARγ activation, suggesting that PPRE1 plays a critical role in regulating FABP4 transcription ( Figure 6G ). Tamoxifen and 4-hydroxytamoxifen partially inhibited the activity of the PPRE1-or the PPRE2-deleted promoter owing to the existence of the nGRE in these promoters ( Figure 6G ).
The effects of tamoxifen on the activity of GR and PPARγ were further investigated by an EMSA to assess the binding of nuclear proteins to the nGRE and PPRE1 in response to tamoxifen treatment. As expected, tamoxifen and 4-hydroxytamoxifen enhanced the binding of the nGRE with nuclear proteins ( Figure 7A ). In contrast, tamoxifen and 4-hydroxytamoxifen reduced the affinity of PPRE1 to nuclear proteins ( Figure 7B ). The binding of the nGRE or PPRE1 with nuclear proteins was partially reduced by an anti-GR antibody (lane 5 compared with the lane 6 in Figure 7A ) or by an anti-PPARγ antibody (the first lane compared with the last lane in Figure 7B ) indicating specific binding. In addition, the results in ChIP assays indicated a strong interaction between PPRE1 and PPARγ protein, and a weak interaction between nGRE and GR protein ( Figure 7C ). However, tamoxifen and 4-hydroxytamoxifen reduced the interaction of PPRE1-PPARγ but enhanced the interaction of nGRE-GR ( Figure 7C ). Taken together, these results further indicate that tamoxifen inhibits macrophage FABP4 expression at the transcriptional level by inactivating GR and PPARγ pathways. 
Tamoxifen inhibits FABP4 expression in vivo and human macrophage FABP4 expression
To define the in vivo effect of tamoxifen on FABP4 expression, we fed apoE − / − mice a high-fat diet or a diet containing tamoxifen (2 mg/100 g of food) for 1 month. We then determined changes in FABP4 protein expression in peritoneal macrophages. The results in Figure 8 (A) indicate that administration of mice with tamoxifen reduced macrophage FABP4 expression in vivo. In addition to macrophages, FABP4 is also highly expressed in adipocytes. Therefore we collected both white and brown adipose tissue samples from mice after tamoxifen treatment. The results in Figure 8 (B) indicate that tamoxifen also inhibited FABP4 expression in adipose tissues in vivo. To determine the effect of tamoxifen on circulating FABP4 levels, we also collected the blood samples after treatment and determined serum FABP4 levels by ELISA. The results in Figure 8 (C) indicate that tamoxifen reduced circulating FABP4 levels similarly between female and male mice (by approximately one-third; female, 20.8 compared with 14.1 μg/l; male, 18.4 compared with 12.0 μg/l). The similar inhibitory effects on macrophage or adipose FABP4 expression or circulating FABP4 levels in vivo between male and female mice further confirm that the regulation of FABP4 expression by tamoxifen is sex-independent.
Finally, to determine the effects of tamoxifen on human macrophage FABP4 protein expression, we isolated human monocytes from blood and differentiated them into macrophages. We then treated the cells with tamoxifen or 4-hydroxytamoxifen alone or in the presence of troglitazone. Similar to mouse macrophages, we observed that tamoxifen and 4-hydroxytamoxifen inhibited human macrophage FABP4 protein expression in a dose-dependent manner ( Figure 9A ). Furthermore, tamoxifen decreased PPARγ -induced human macrophage FABP4 protein expression ( Figure 9B ).
DISCUSSION
A lower incidence of cardiovascular disease is observed among women than men in the age group 20-39 years owing to the endogenous production of oestrogen in women [32] . However, this gap narrows with advancing age, indicating that cardiovascular disease can contribute to a significant health threat to older post-menopausal women, independent of breast cancer. Tamoxifen, as an adjuvant therapy for breast cancer, has been observed to possess several pleiotropic functions, including cardioprotection [33, 34] . At the molecular level, tamoxifen functions as an antioxidant to protect LDL particles from oxidative damage and lipid peroxidation [35, 36] . It also inhibits cholesterol biosynthesis by inhibiting 8 isomerase and 24 reductase [37, 38] . Tamoxifen alone, and with lovastatin, can enhance LDLR (LDL receptor) expression which contributes to the hypolipidaemic effect of tamoxifen [39] . Clinically, patients receiving tamoxifen treatment have reduced total and LDLcholesterol levels [40, 41] . Formation of macrophage/foam cells is the initial and critical step in the development of atherosclerosis. We have previously reported that both tamoxifen and 4-hydroxytamoxifen induce macrophage SR-BI (scavenger receptor BI) expression in a sex-dependent manner, indicating another mechanism by which tamoxifen inhibits macrophage/foam cell formation [42] . However, some of the cardioprotective effects of tamoxifen occur in both males and females, indicating that tamoxifen can also function in a sex-independent manner. Indeed, in the present study we observed that tamoxifen and 17β-oestradiol inhibit FABP4 expression in macrophages isolated from male and female wild-type mice, and fulvestrant has little effect ( Figure 2 ). More importantly, our in vivo study demonstrates a similar inhibitory effect of tamoxifen on FABP4 expression in macrophages and adipose tissues, and circulating FABP4 levels between male
Figure 8 Tamoxifen inhibits FABP4 expression in vivo
Both male and female apoE − / − mice were fed a high-fat diet or the diet containing tamoxifen (2 mg/100 g of food) for 1 month. At the end of experiment, peritoneal macrophages (A) and both white and brown adipose tissues (B) were collected and total proteins were extracted, followed by determination of FABP4 protein expression by Western blot analysis. (C) Mouse serum samples were prepared and used to determine circulating FABP4 levels by ELISA. *P < 0.05 (n = 5), significantly different from the corresponding control. Ctrl, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 9 Tamoxifen and 4-hydroxytamoxifen inhibit human blood-derived macrophage FABP4 protein expression
Human monocytes were isolated from blood and differentiated into macrophages as described in the Materials and methods section. The human macrophages were treated with tamoxifen or 4-hydroxytamoxifen at the concentrations indicated in the absence (A) or presence (B) of 2 μM troglitazone overnight. Expression of human macrophage FABP4 protein was determined by Western blot analysis. Ctrl, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 4-OH Tam, 4-hydroxytamoxifen.
and female mice (Figure 8 ). These findings confirm that the regulatory effect of tamoxifen on FABP4 expression is independent of sex. Meanwhile, we demonstrate for the first time that the inhibition of macrophage FABP4 expression by tamoxifen occurs through the combined effects of GR and PPARγ , the two classical signalling pathways regulating FABP4 expression (Figures 3  and 5-7) . FABP4 expression is highly induced during fibroblast/ adipocyte and monocyte/macrophage differentiation. Activation of PPARγ by ligands or oxLDL can induce FABP4 expression in monocyte/macrophages [29, 30] . Tamoxifen blocks the induction of FABP4 expression induced by troglitazone or oxLDL ( Figure 5) , suggesting an involvement of PPARγ in the inhibition of macrophage FABP4 expression by tamoxifen. Indeed, tamoxifen and 4-hydroxytamoxifen inhibited PPARγ expression that can result in a decreased interaction between PPARγ and PPRE1 in the FABP4 gene ( Figures 5D, 7B and 7C ). Two putative PPREs were found in the distal region of the Fabp4 promoter ( Figure 6A) ; deletion of PPRE1, but not PPRE2, profoundly altered the promoter activity in response to treatment ( Figure 6G ), since PPRE1 has more nucleotides than PPRE2 which are identical with the conserved PPRE sequence ( Figure 6A ). GR, a typical transcription factor, functions after ligand-induced nuclear translocation. Activation of GR induces transcription of target genes containing the pGRE alone. It can also inhibit transcription of some genes containing the nGRE alone. However, the transcription of genes containing both the pGRE and nGRE, such as FABP4, is determined by activity of these two elements [7, 43] . Dexamethasone alone activates GR nuclear translocation and pGRE, thereby inducing macrophage FABP4 expression [27] . The statins alone reduce macrophage FABP4 expression [8] . However, statins synergize dexamethasone-induced FABP4 transcription since they can suppress nGRE activity [7] . In the present study, we observed that tamoxifen has little effect on GR expression as well as dexamethasone-induced nuclear translocation, yet dexamethasone-induced FABP4 expression and promoter activity remain decreased by tamoxifen ( Figures 3A,  4A and 6C) . Interestingly, the dexamethasone-activated Fabp4 promoter with nGRE deletion is little affected by tamoxifen ( Figure 6D ), suggesting an important role of the nGRE in the tamoxifen-inhibited macrophage FABP4 expression. In fact, the results of EMSA and ChIP assays suggest that tamoxifen enhances the interaction between GR and nGRE ( Figures 7A  and 7C ).
Taken together, we observed that tamoxifen inactivates PPARγ by reducing its expression. Meanwhile, it reduces GR activity by activating the nGRE. Therefore the results of the present study suggest that tamoxifen inhibits macrophage FABP4 expression through the combined effects of GR and PPARγ signalling pathways. Such findings suggest that the inhibition of FABP4 expression can result from the anti-atherosclerotic properties of tamoxifen.
